RemeGen Announces Continued Inclusion of Telitacicept and Disitamab Vedotin in China National Reimbursement Drug List, Ensuring Continuous Accessibility of Innovative Drugs for More Patients ...Middle East

YANTAI, China, Dec. 18, 2023 /PRNewswire/ -- RemeGen Co. Ltd. ("RemeGen" or "the Company") (9995.HK, SHA: 688331), a commercial-stage biotechnology company, has recently confirmed that under the 2023 simple renewal mechanism of China National Healthcare Security Administration (NHSA), on...

Hence then, the article about remegen announces continued inclusion of telitacicept and disitamab vedotin in china national reimbursement drug list ensuring continuous accessibility of innovative drugs for more patients was published today ( Monday 18/12/2023 - 03:44 PM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( RemeGen Announces Continued Inclusion of Telitacicept and Disitamab Vedotin in China National Reimbursement Drug List, Ensuring Continuous Accessibility of Innovative Drugs for More Patients )

Also on site :

• Woman accused of physically abusing five children at unlicensed daycare in Gates
• Olivia Wilde describes mortifying interaction with Tom Cruise after ‘f–ked up’ custody papers attack
• Several Israeli strikes hit southern Lebanon, state media reports